know more about us

Our work is defined by our patient pledge: ‘With You Until PH Isn’t’


At Janssen, we are spearheading a new era for pulmonary hypertension (PH), working to transform the disease into a long-term manageable condition, so that patients can live a normal life. Supported by Actelion’s 20-year heritage of pioneering innovation, we are working to reach more patients and aim to help tackle the diagnosis gap that is delaying access to the care that patients need.

We want to use our full range of resources to tackle PH. From investment in research and development to innovation in medical devices and diagnostics, our commitment to building an innovative drug development pipeline is real. We’re focused not only on how we treat PH but on a broader spectrum of goals for the PH community. That includes enhancing patient care, as well as advocating and educating to facilitate faster diagnosis.